EUVIMEDEUVIMED entdecken
Open Access

Evaluation of Intestinal Permeability Using Serum Biomarkers in Learning Early About Peanut Allergy Trial

Ozge Nur Aktas iD, Allyson Mateja iD, Min Jenny Li iD, Lindsay Chatman iD, Megan C Grieco iD, Carolyn H Baloh iD, Michelle Huffaker iD, Lisa M Wheatley iD, George du Toit iD, Gideon Lack iD, Erica Brittain iD, Pamela A Frischmeyer-Guerrerio iD

Allergy · 2025

DOI: 10.1111/all.16464 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, 2025. Verfasst von Ozge Nur Aktas und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Peanut Hypersensitivity, Biomarkers, Intestinal Mucosa. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intestinal barrier dysfunction may lead to a break in tolerance and development of food allergy (FA). There is contradictory evidence on whether intestinal permeability (IP) is altered in IgE‐mediated FA. Thus, we sought to determine whether IP differed between children with eczema who did (FA group) or did not (atopic controls, ACs) develop FA and whether peanut sensitization, allergy, and early introduction impacted IP using serum biomarkers zonulin, soluble CD14, and Intestinal Fatty Acid Binding Protein among randomly selected participants enrolled in the Learning Early About Peanut allergy trial.

Methods

FA group was defined as having at least one FA at either baseline (4–11 months) or 60 months of age (V60). ACs had eczema at baseline and no FA at either visit. Serum IP markers (sIPMs) were measured by ELISA at baseline and V60, and their relationship with the clinical characteristics of participants was analyzed using parametric tests and linear regression models.

Results

We evaluated 237 FA subjects and 76 ACs. sIPM levels were similar in FA subjects and ACs at baseline and V60. Age when the child first developed any FA (< 1 year vs. > 1 year), eczema severity, peanut sensitization, peanut allergy, and early peanut introduction were not statistically significantly associated with sIPM levels. Total IgE and eosinophil levels, peanut‐specific IgE, IgG4, and IgG4/IgE ratio were not correlated with sIPM levels.

Conclusions

No differences in sIPMs were detected to support altered IP in infants with FA compared to ACs or following early peanut introduction among peanut‐sensitized children.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peanut HypersensitivityBiomarkersIntestinal MucosaHumansFemaleMaleChild, PreschoolInfantPermeabilityImmunoglobulin ELipopolysaccharide ReceptorsFatty Acid-Binding ProteinsCholera ToxinArachisIntestinal Barrier FunctionHaptoglobinsProtein Precursors

Stichwörter der Autor:innen

atopic dermatitiseczemafood allergyintestinal permeabilityserum biomarkers

Substanzen

BiomarkersImmunoglobulin ELipopolysaccharide ReceptorsFatty Acid-Binding ProteinsCholera ToxinzonulinHaptoglobinsProtein Precursors

Autor:innen und Institutionen

  • Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, Maryland, USA.
  • Division of Allergy and Immunology, Children's National Hospital, Washington, District of Columbia, USA.
  • Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
  • Biostatistics Research Branch, NIAID, NIH, North Bethesda, Maryland, USA.
  • Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Immune Tolerance Network, Benaroya Research Institute at Virginia Mason, Seattle, Washington, USA.

ORCID-Profile: Ozge Nur Aktas, Allyson Mateja, Min Jenny Li, Lindsay Chatman, Megan C Grieco, Carolyn H Baloh, Michelle Huffaker, Lisa M Wheatley, George du Toit, Gideon Lack, Erica Brittain, Pamela A Frischmeyer-Guerrerio

Förderung

  • NIAID NIH HHS
  • NCI NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • Division of Intramural Research, National Institute of Allergy and Infectious Diseases
  • Intramural NIH HHS
  • National Cancer Institute
  • Division of Intramural Research

Zitieren

APA

Aktas, O. N., Mateja, A., Li, M. J., Chatman, L., Grieco, M. C., Baloh, C. H., Huffaker, M., Wheatley, L. M., du Toit, G., Lack, G., Brittain, E., & Frischmeyer-Guerrerio, P. A. (2025). Evaluation of Intestinal Permeability Using Serum Biomarkers in Learning Early About Peanut Allergy Trial. Allergy. https://doi.org/10.1111/all.16464

Vancouver

Aktas ON, Mateja A, Li MJ, Chatman L, Grieco MC, Baloh CH, et al. Evaluation of Intestinal Permeability Using Serum Biomarkers in Learning Early About Peanut Allergy Trial. Allergy. 2025. doi:10.1111/all.16464

BibTeX
@article{Aktas2025,
  author = {Aktas, Ozge Nur and Mateja, Allyson and Li, Min Jenny and Chatman, Lindsay and Grieco, Megan C and Baloh, Carolyn H and Huffaker, Michelle and Wheatley, Lisa M and du Toit, George and Lack, Gideon and Brittain, Erica and Frischmeyer-Guerrerio, Pamela A},
  title = {Evaluation of Intestinal Permeability Using Serum Biomarkers in Learning Early About Peanut Allergy Trial},
  journal = {Allergy},
  year = {2025},
  doi = {10.1111/all.16464}
}
Kostenlos starten →